The scientist, Dr. Fiona Havers, told colleagues at the Centers for Disease Control and Prevention on Monday that she no ...

Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the ...

Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's ...

The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...

Fiona Havers, who oversaw CDC respiratory virus data, told colleagues she no longer had confidence the data would be used objectively to set vaccine policy.

A Seattle infectious disease doctor, whose work was pivotal early in the COVID pandemic, shares more on her experience with ...

Investing.com -- A senior scientist at the U.S. Centers for Disease Control and Prevention (CDC) resigned Monday, expressing concerns about how COVID-19 and RSV hospitalization data would be used by ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

(Reuters) -Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's respiratory syncytial virus vaccine in a broader age group.

With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower ...